Oxford BioTherapeutics and Boehringer Ingelheim build on their successful partnership

  • In October, Oxford BioTherapeutics (OBT) received a milestone payment from Boehringer Ingelheim (BI) for the progression of the first bispecific oncology drug candidate, developed under their collaboration, into Phase I clinical trials.
  • In addition, OBT established a new, expanded collaboration with BI, whereby OBT will validate certain novel oncology drug targets that are compatible for targeting with various antibody drug formats across a range of cancer indications. These targets were identified using OBT’s OGAP® discovery platform.
  • Following completion of these activities, BI will have the exclusive right to develop and commercialise these oncology products for selected programs.
  • OBT will receive an upfront milestone and full-time equivalent funding for its activities under the collaboration.

OBT, a clinical stage oncology company committed to the discovery and development of therapies for various cancer types, announced the expansion of its collaboration with BI to discover novel selective tumor targets as first bispecific antibody advanced into the clinic.

BI will use OBT’s OGAP® platform to identify novel target opportunities for new immunotherapies utilizing their Tcell engager, cancer vaccine, and oncolytic virus platforms. This follows the initiation of the first patient dosing in a Phase 1 clinical trial of a bispecific antibody for the treatment of patients with small cell lung carcinoma and other neoplasms, where the target for the bispecific antibody was discovered during the first phase of the partnership.

In addition to the programs in the partnership with Boehringer Ingelheim, OBT’s clinical assets have also been enabled through the OGAP® discovery platform. Selecting the right target is fundamental for the successful development of a truly first in class oncology product. OBT’s platforms are designed to discover novel therapeutic targets and engineer antibodies to those targets, including CAR-T, other Tcell and NK cell-mediated cytotoxicity (ADCC) therapeutics to best address difficult-to-treat cancers. A major differentiator between OBTs discovery platform and other approaches is the retention of the link between individual patient samples through to the design of therapeutic antibodies and diagnostic patient selection tools, increasing the overall successful transition into clinical development.

Paul Adam, Ph.D., Department Head, Cancer Immunology & Immune Modulation Research at Boehringer Ingelheim commented: “We look forward to furthering our successful collaboration with Oxford BioTherapeutics and advancing our cancer immunology portfolio of novel therapies.”

Christian Rohlff, Ph.D., Chief Executive Officer of OBT said: “We view the hopeful discovery of additional tumor targets as further confirmation of the value of our OGAP® platform to identify novel targets that can be substrates for innovative new therapies… OBT’s platforms are designed to discover and validate novel therapeutic targets and we look forward to continuing our partnership with Boehringer Ingelheim to best address difficult-to-treat cancers.”